Advertisement

Journal of Bone and Mineral Metabolism

, Volume 30, Issue 4, pp 468–473 | Cite as

A study of changes in bone metabolism in cases of gender identity disorder

  • Tsuyoshi MiyajimaEmail author
  • Yoon Taek Kim
  • Hiromi Oda
Original Article

Abstract

The aim of this study was to determine the effect of increasing estrogen and decreasing androgen in males and increasing androgen and decreasing estrogen in females on bone metabolism in patients with gender identity disorder (GID). We measured and examined bone mineral density (BMD) and bone metabolism markers retrospectively in GID patients who were treated in our hospital. In addition, we studied the effects of treatment on those who had osteoporosis. Patients who underwent a change from male to female (MtF) showed inhibition of bone resorption and increased L2–4 BMD whereas those who underwent a change from female to male (FtM) had increased bone resorption and decreased L2–4 BMD. Six months after administration of risedronate to FtM patients with osteoporosis, L2–4 BMD increased and bone resorption markers decreased. These results indicate that estrogen is an important element with regard to bone metabolism in males.

Keywords

Gender identity disorder Bone mineral density Bone metabolism marker Sex hormone Transgender 

References

  1. 1.
    Swaab DF, Fliers E (1985) Sexually dimorphic nucleus in the human brain. Science 228:1112–1115PubMedCrossRefGoogle Scholar
  2. 2.
    Swaab DF, Hofman MA (1995) Sexual differentiation of the human hypothalamus in relation to gender and sexual orientation. Trends Neurosci 18:264–270PubMedGoogle Scholar
  3. 3.
    Jiang-Ning Zhou, Hofman MA, Gooren Louis JG, Swaab Dick F (1995) A sex difference in the human brain and its relation to transsexuality. Nature 378:68–70CrossRefGoogle Scholar
  4. 4.
    WHO (1992) The ICD-10 classifications of mental and behavioral disorders. WHO, GenevaGoogle Scholar
  5. 5.
    American Psychiatric Association (1993) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DCGoogle Scholar
  6. 6.
    Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, Gooren LJ, Meyer III WJ, Spack NP, Tangpricha V, Montori VM (2009) Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 94:3132–3154Google Scholar
  7. 7.
    Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR (2004) Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendation for diagnosis and therapies. Cancer 100:892–899PubMedCrossRefGoogle Scholar
  8. 8.
    Marshall D, Johnell O, Wedel H (1996) Meta analysis of how well measures of bone mineral density predict occurrence osteoporotic fractures. BMJ 312:1254–1259PubMedCrossRefGoogle Scholar
  9. 9.
    Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstorm D, Meunier PJ, Melton LJ, O’Neill T, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Predictive valueof BMD for hip and other fractures. J Bone Miner Res 20:1185–1194PubMedCrossRefGoogle Scholar
  10. 10.
    Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, Fujiwara S, Kroger H, McClosky EV, Mellstorm D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Smoking and fracture risk: a meta analysis. Osteoporosis Int 16:155–162CrossRefGoogle Scholar
  11. 11.
    Vestergaard P, Mosekilde L (2003) Fracture risk associated with smoking: a metaanalysis. J Intern Med 254:572–583PubMedCrossRefGoogle Scholar
  12. 12.
    Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA, Pols H, Tenenhouse A (2005) Alcohol intake as a risk factor for fracture. Osteoporosis Int 16:737–742CrossRefGoogle Scholar
  13. 13.
    Kanis JA, Johansson H, Oden A, Johnell O, Delaet C, Eisman JA, McCloskey EV, Mellstrom D, Melton LJ, Pols HAP, Reeve J, Silman AJ, Tenenhouse A (2004) A family history of fracture and fracture risk: a metaanalysis. Bone 35:1029–1037PubMedCrossRefGoogle Scholar
  14. 14.
    Japan Osteoporosis Society (2005) Guidelines for the use of biochemical markers of bone turnover in osteoporosis. J Bone Miner Metab 23:97–104Google Scholar
  15. 15.
    Gooren LJG, Giltay EJ (2008) Review of studies of androgen treatment of female to male transsexuals: effects and risks of administration of androgens to females. J Sex Med 5:765–776PubMedCrossRefGoogle Scholar
  16. 16.
    T’Sjoen G, Steven W, Youri T, Bruno L, Kaatje T, Goemaere S, Jean-Marc K (2009) Prevalence of low bone mass in relation to estrogen treatment and body composition in male-to-female transsexual persons. J Clin Densitom 12:306–313PubMedCrossRefGoogle Scholar
  17. 17.
    Greenspan SL (2008) Approach to the prostate cancer patient with bone disease. J Clin Endocrinol Metab 93:2–7PubMedCrossRefGoogle Scholar
  18. 18.
    Vanderschueren D, Gaytant J, Boonen S, Venken K (2008) Androgen and bone. Curr Opin Endocrinol Diabetes Obes 15:250–254PubMedCrossRefGoogle Scholar
  19. 19.
    Smith EP, Boyd J, Frank GR, Takahashi H, Gohen RM, Specker B, Wiliams TG, Lubahn DB, Korach KS (1994) Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. New Engl J Med 331:1056–1061PubMedCrossRefGoogle Scholar
  20. 20.
    Bonnick S, Kenneth SG, Douglas KP, McClung M, Hochberg M, Burnett SM, Sebba A, Kagan R, Chen E, Thompson DE, de Papp AE (2006) Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 91:2631–2637PubMedCrossRefGoogle Scholar
  21. 21.
    Page ST, Marck BT, Tolliver JM, Matsumoto AM (2008) Tissue selectivity of the anabolic steroid 19-nor-4-androstenediol-3β, 17β-diol in male Sprague Dawley rats: selective stimulation of muscle mass and bone mineral density relative to prostate mass. Endocrinology 149:1987–1993PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer 2012

Authors and Affiliations

  • Tsuyoshi Miyajima
    • 1
    • 2
    Email author
  • Yoon Taek Kim
    • 1
  • Hiromi Oda
    • 1
  1. 1.Department of Orthopedic SurgerySaitama Medical UniversitySaitamaJapan
  2. 2.Outpatient Department for Osteoporosis, Kawagoe ClinicSaitama Medical UniversitySaitamaJapan

Personalised recommendations